USANA Health Sciences Files 8-K on Financials
Ticker: USNA · Form: 8-K · Filed: Apr 30, 2024 · CIK: 896264
| Field | Detail |
|---|---|
| Company | Usana Health Sciences Inc (USNA) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, disclosure, sec-filing
Related Tickers: USNA
TL;DR
USANA Health Sciences dropped an 8-K on April 30th detailing their financial condition. Check it out.
AI Summary
On April 30, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes financial statements and exhibits, indicating a report on the company's operational and financial condition.
Why It Matters
This filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing (8-K) and does not inherently present new risks.
Key Players & Entities
- USANA HEALTH SCIENCES, INC. (company) — Registrant
- April 30, 2024 (date) — Date of Report
- 3838 West Parkway Boulevard (location) — Principal executive offices address
- Salt Lake City, Utah (location) — Principal executive offices city and state
- 8019547100 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for USANA Health Sciences?
The primary purpose is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits as of April 30, 2024.
When was this 8-K report filed?
The report was filed on April 30, 2024.
What is USANA Health Sciences' principal executive office address?
The principal executive offices are located at 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.
What is the SIC code for USANA Health Sciences?
The Standard Industrial Classification (SIC) code for USANA Health Sciences is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.
What is the company's state of incorporation?
USANA Health Sciences, Inc. is incorporated in Utah.
Filing Stats: 698 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-30 16:08:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share USNA New York Stock
Filing Documents
- usna-20240430.htm (8-K) — 28KB
- q12024earningsreleaseex991.htm (EX-99.1) — 156KB
- q12024managementcommentary.htm (EX-99.2) — 65KB
- usanacorplogoresized.jpg (GRAPHIC) — 9KB
- usanacorplogoresizedb.jpg (GRAPHIC) — 9KB
- 0000896264-24-000138.txt ( ) — 415KB
- usna-20240430.xsd (EX-101.SCH) — 2KB
- usna-20240430_lab.xml (EX-101.LAB) — 21KB
- usna-20240430_pre.xml (EX-101.PRE) — 12KB
- usna-20240430_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 30, 2024, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the first quarter ended March 30, 2024. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated April 30, 2024 (furnished herewith). 99.2 Management Commentary provided by USANA Health Sciences, Inc. dated April 30, 2024 (furnished herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. USANA HEALTH SCIENCES, INC. By: /s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer Date: April 30, 2024